Immutep Limited - ADR
IMMP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.9M
Close$
$0.02
99.2% downside
Current Fair Value
99.2% downsideOvervalued by 99.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $33.90 Million |
|---|---|
| Enterprise Value | $-33,933,780.00 |
| Earnings per Share | $-10.7 |
| Beta | 2.31 |
| Outstanding Shares | 7,368,606 |
Return
| Return on Equity | -229.50% |
|---|---|
| Return on Assets | -169.59% |
| Return on Invested Capital | -217.89% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 4.04 |
| Price to Sales | 1.51 |
| Price to Book Ratio | 0.38 |
| Enterprise Value to Revenue | -1.56 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
$6.85 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-1.45
Consensus analyst estimateRevenue Estimate
$1.43 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 210.94% |
|---|---|
| Total Calls | 171,800▲ 1242.19% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.13%▼ 0.64% |
|---|---|
| Total Invested | $692,001▼ 24.48% |
| Investors Holding | 25▼ 3.00% |
About Immutep Limited
57 employees
CEO: Marc Voigt
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP32...